The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastrointestinal stromal tumor (GIST) serves as a key model for targeted cancer therapy.
• Most GISTs harbor activating mutations in KIT or platelet-derived growth factor A (PDGFRA) genes.
• GIST exhibits high responsiveness to selective tyrosine kinase inhibitors, transforming its management.

Purpose of the Study:

• To review recent advancements in understanding GIST natural history and molecular biology.
• To discuss progress in risk stratification and drug resistance mechanisms in GIST.
• To highlight the role of surgery and adjuvant imatinib therapy in GIST management.

Main Methods:

• Literature review of recent studies on GIST.
• Analysis of molecular mechanisms driving GIST development and progression.
• Evaluation of clinical trial data for targeted therapies and surgical outcomes.

Main Results:

• Surgery is the only curative option for localized GIST, achieving >50% cure rates.
• Adjuvant imatinib therapy extends recurrence-free survival and potentially overall survival.
• Targeted therapy has converted GIST into a manageable chronic condition for some patients.

Conclusions:

• While surgery is curative for localized disease, targeted therapies have revolutionized GIST treatment.
• Future management strategies may involve molecular subtyping for combined or sequential tyrosine kinase inhibitor use.
• Continued research into GIST molecular biology and drug resistance is crucial for further therapeutic advancements.